Surging Tamiflu sales boost Chugai's third quarter
This article was originally published in Scrip
Executive Summary
Tamiflu (oseltamivir) sales of ¥55.8 billion ($607.8 million) in the nine months to September 30th boosted overall sales at Chugai, Roche's Japanese subsidiary, by 35% to ¥303.4 billion over the same period.